| Code | CSB-RA723415MB10HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to mupadolimab, targeting NT5E (CD73), an ecto-5'-nucleotidase anchored to the cell surface. NT5E catalyzes the conversion of extracellular adenosine monophosphate to adenosine, a potent immunosuppressive molecule that inhibits T cell and NK cell function while promoting regulatory T cell activity. This enzyme is frequently overexpressed in various solid tumors, where it contributes to the creation of an immunosuppressive tumor microenvironment that facilitates immune evasion and tumor progression. Elevated NT5E expression has been associated with poor prognosis in multiple cancer types, including triple-negative breast cancer, ovarian cancer, and melanoma.
Mupadolimab is a therapeutic antibody designed to block NT5E enzymatic activity, thereby reducing adenosine production and reversing tumor-mediated immunosuppression. This biosimilar provides researchers with a valuable tool for investigating adenosine-mediated immune regulation, tumor immunology, and the therapeutic potential of targeting the adenosine pathway in cancer. It supports studies exploring combination strategies with other immunotherapies and investigations into NT5E's role in the tumor microenvironment.
There are currently no reviews for this product.